Jacob Plieth of Evaluate writes about TC Biopharm’s treatment of the first patient cohort in a study of OmnImmune (TCB002), which represents the fourth clinical trial involving gamma-delta cells in the West. The UK biotech venture reports that the trial is a prelude to going into the clinic with a gamma-delta CAR-T cell product (perhaps a first) later this year.
TC reports that the purpose of the OmnImmune study is to demonstrate the safety of injecting expanded but unmodified, donor-derived gamma-delta T cells into nine acute myelogenous leukemia patients.
Other trials include Gadeta’s TEG001 and an academic study of OmnImmune, while an Innate Pharma study at Rennes University Hospital was terminated a decade ago. China is an area of activity and Plieth refers the reader to deal activity involving Gamma-delta.Source: Evaluate